Santarus Secures $100M Settlement from Par PharmaceuticalsPrint PDF
On September 22, 2014, Par Pharmaceuticals agreed to pay $100 million to Irell client Santarus Inc., now owned by Salix Pharmaceuticals, and the curators of the University of Missouri to settle the patent infringement dispute over Par's sales of a generic version of Zegerid. The case was scheduled for trial in the District of Delaware in November 2014. Par agreed to the settlement just three days before the pretrial conference. The Irell team included Morgan Chu, Gary Frischling and Amy Proctor.